EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?

Tanya M Laidlaw, Andrew A White

The Journal of Allergy and Clinical Immunology: In Practice · 2024

DOI: 10.1016/j.jaip.2023.09.019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024. Verfasst von Tanya M Laidlaw und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. Electronic address: tlaidlaw@partner…. Hauptthemen laut MEDLINE: Asthma, Aspirin-Induced, Respiration Disorders, Sinusitis, Asthma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health, NIAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There has been a paradigm shift in the management of aspirin-exacerbated respiratory disease (AERD). It started in 2015 when the first biologic was Food and Drug Administration (FDA) approved for severe eosinophilic asthma. Thus, there emerged a new era in the treatment of patients with type 2-mediated airway diseases. This has led to an increasing number of options for patients, undoubtably a great thing, but has left clinicians without a clear answer for how to balance the therapies that exist for AERD, what to recommend for treatment, and how to best assess the benefits and risks of each therapy. This paper aims to explore these benefits and risks, and to provide a roadmap for future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Asthma, Aspirin-InducedRespiration DisordersSinusitisAsthmaBiological ProductsNasal PolypsRhinitisHumansAspirinDesensitization, ImmunologicChronic Disease

Stichwörter der Autor:innen

AERDAspirin desensitizationAspirin-exacerbated respiratory diseaseBenralizumabCRSwNPChronic rhinosinusitisDupilumabMepolizumabNasal polypsOmalizumab

Substanzen

AspirinBiological Products

Autor:innen und Institutionen

  • Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. Electronic address: tlaidlaw@partners.org.
  • Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif.

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • NIAID

Zitieren

APA

Laidlaw, T. M., & White, A. A. (2024). Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.09.019

Vancouver

Laidlaw TM, White AA. Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?. The Journal of Allergy and Clinical Immunology: In Practice. 2024. doi:10.1016/j.jaip.2023.09.019

BibTeX
@article{Laidlaw2024,
  author = {Laidlaw, Tanya M and White, Andrew A},
  title = {Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  doi = {10.1016/j.jaip.2023.09.019}
}
Kostenlos starten →